316 related articles for article (PubMed ID: 34153155)
1. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
[TBL] [Abstract][Full Text] [Related]
2. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
3. Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study.
Draper BL; Pedrana A; Howell J; Yee WL; Htay H; Aung KS; Shilton S; Kyi KP; Naing W; Hellard M
JMIR Res Protoc; 2020 Jul; 9(7):e16863. PubMed ID: 32673260
[TBL] [Abstract][Full Text] [Related]
4. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
6. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
[TBL] [Abstract][Full Text] [Related]
7. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
8. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
9. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar.
Min Thaung Y; Chasela CS; Chew KW; Minior T; Lwin AA; Sein YY; Drame N; Marange F; van der Horst C; Thwin HT; Freiman MJ; Gandhi MM; Bijl M; Wose Kinge C; Rosen S; Thura S; Mohamed S; Xulu T; Naing AY; Barralon M; Cavenaugh C; Kyi KP; Sanne I;
J Viral Hepat; 2021 Jan; 28(1):147-158. PubMed ID: 32935438
[TBL] [Abstract][Full Text] [Related]
11. Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.
Hassan MRA; Chan HK; Nordin M; Yahya R; Sulaiman WRW; Merican SAA; Lah D; Sem X; Shilton S
Harm Reduct J; 2023 Apr; 20(1):48. PubMed ID: 37046294
[TBL] [Abstract][Full Text] [Related]
12. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
13. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a decentralized, community-based "one-stop-shop" hepatitis C testing and treatment program in Yangon, Myanmar.
Win TM; Draper BL; Palmer A; Htay H; Sein YY; Shilton S; Kyi KP; Hellard M; Scott N
JGH Open; 2023 Nov; 7(11):755-764. PubMed ID: 38034058
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
[TBL] [Abstract][Full Text] [Related]
17. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.
Marquez LK; Chaillon A; Soe KP; Johnson DC; Zosso JM; Incerti A; Loarec A; Nguyen A; Walker JG; Mafirakureva N; Lo Re Iii V; Wynn A; McIntosh C; Kiene SM; Brodine S; Garfein RS; Vickerman P; Martin NK
BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33627360
[TBL] [Abstract][Full Text] [Related]
18. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
Morris MD; McDonell C; Luetkemeyer AF; Thawley R; McKinney J; Price JC
JAMA Netw Open; 2023 Oct; 6(10):e2338792. PubMed ID: 37862013
[TBL] [Abstract][Full Text] [Related]
19. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
20. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
